Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Qureshi, Huma ^a,b   Genescà, Meritxell ^a,b   Fritts, Linda ^a   McChesney, Michael B ^a   Robert Guroff, Marjorie ^c   Miller, Christopher J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; FAS ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 1; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; CHEMOKINE;

ADAPTIVE IMMUNITY; ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN ADENOVIRUS 5; INNATE IMMUNITY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; REINFECTION; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; VIRUS SHEDDING; ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMAL; BLOOD; CELL COUNT; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VACCINATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CHEMOKINES; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; MACACA MULATTA; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; VACCINATION; VIRUS SHEDDING;

EID: 84929518940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106004     Document Type: Article

References (63)

1. Chany C, Lepine P, Lelong M, Le TV, Satge P, et al. (1958) Severe and fatal pneumonia in infants and young children associated with adenovirus infections. Am J Hyg 67: 367-378.
2. Edwards KM, Thompson J, Paolini J, Wright PF (1985) Adenovirus infections in young children. Pediatrics 76: 420-424.
3. Evans AS (1958) Adenovirus infections in children and young adults; with comments on vaccination. N Engl J Med 259: 464-468.
4. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84: 570-573.
5. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, et al. (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
6. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, et al. (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11: 351-357.
7. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, et al. (2006) Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 44: 3781-3783.
8. Alkhalaf MA, Guiver M, Cooper RJ (2013) Prevalence and quantitation of adenovirus DNA from human tonsil and adenoid tissues. J Med Virol 85: 1947- 1954.
9. Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, et al. (2012) Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIVspecific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 19: 629-637.
10. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, et al. (2009) Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 83: 2623-2631.
11. Roy S, Calcedo R, Medina-Jaszek A, Keough M, Peng H, et al. (2011) Adenoviruses in lymphocytes of the human gastro-intestinal tract. PLoS One 6: E24859.
12. Muruve DA (2004) The innate immune response to adenovirus vectors. Hum Gene Ther 15: 1157-1166.
13. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ (2002) The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 13: 129- 141.
14. Friedman JM, Horwitz MS (2002) Inhibition of tumor necrosis factor alphainduced NF-kappa B activation by the adenovirus E3-10.4/14.5K complex. J Virol 76: 5515-5521.
15. Jefferies WA, Burgert HG (1990) E3/19K from adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J Exp Med 172: 1653-1664.
16. Lesokhin AM, Delgado-Lopez F, Horwitz MS (2002) Inhibition of chemokine expression by adenovirus early region three (E3) genes. J Virol 76: 8236-8243.
17. Schaack J, Bennett ML, Colbert JD, Torres AV, Clayton GH, et al. (2004) E1A and E1B proteins inhibit inflammation induced by adenovirus. Proc Natl Acad Sci USA 101: 3124-3129.
18. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH (2012) Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86: 625-629.
19. Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86: 1267-1272.
20. Cheng C, Gall JG, Nason M, King CR, Koup RA, et al. (2010) Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84: 630-638.
21. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, et al. (2010) Adenovirus-specific human T cells are pervasive, polyfunctional, and crossreactive. Vaccine 28: 1932-1941.
22. Kessler T, Hamprecht K, Feuchtinger T, Jahn G (2010) Dendritic cells are susceptible to infection with wild-type adenovirus, inducing a differentiation arrest in precursor cells and inducing a strong T-cell stimulation. J Gen Virol 91: 1150-1154.
23. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, et al. (2008) Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82: 546-554.
24. Onion D, Crompton LJ, Milligan DW, Moss PA, Lee SP, et al. (2007) The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein. J Gen Virol 88: 2417-2425.
25. Tang J, Olive M, Champagne K, Flomenberg N, Eisenlohr L, et al. (2004) Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther 11: 1408-1415.
26. Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, et al. (2014) Firstin- Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). J Infect Dis.
27. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
28. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, et al. (2011) Pre- Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans. PLoS One 6: E18526.
29. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46: 1769-1781.
30. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, et al. (2012) Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109: E3503-E3512.
31. Klessig DF, Grodzicker T (1979) Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17: 957-966.
32. Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86: 2239-2250.
33. Chung E, Amrute SB, Abel K, Gupta G, Wang Y, et al. (2005) Characterization of virus-responsive plasmacytoid dendritic cells in the rhesus macaque. Clin Diagn Lab Immunol 12: 426-435.
34. Abel K, Wang Y, Fritts L, Sanchez E, Chung E, et al. (2005) Deoxycytidyl- Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells. Clin Diagn Lab Immunol 12: 606-621.
35. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
36. Buimovici-Klein E, Lange M, Ong KR, Grieco MH, Cooper LZ (1988) Virus isolation and immune studies in a cohort of homosexual men. J Med Virol 25: 371-385.
37. Cinek O, Witso E, Jeansson S, Rasmussen T, Drevinek P, et al. (2006) Longitudinal observation of enterovirus and adenovirus in stool samples from Norwegian infants with the highest genetic risk of type 1 diabetes. J Clin Virol 35: 33-340.
38. Hillis WD, Cooper MR, Bang FB (1973) Adenovirus infections in West Bengal. I. Persistence of viruses in infants and young children. Indian J Med Res 61: 980-988.
39. Lew JF, Moe CL, Monroe SS, Allen JR, Harrison BM, et al. (1991) Astrovirus and adenovirus associated with diarrhea in children in day care settings. J Infect Dis 164: 673-678.
40. Wong S, Pabbaraju K, Pang XL, Lee BE, Fox JD (2008) Detection of a broad range of human adenoviruses in respiratory tract samples using a sensitive multiplex real-time PCR assay. J Med Virol 80: 856-865.
41. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
42. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356.
43. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, et al. (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3: E25.
44. Lore K, Adams WC, Havenga MJ, Precopio ML, Holterman L, et al. (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179: 1721-1729.
45. Rozis G, deSilva S, Benlahrech A, Papagatsias T, Harris J, et al. (2005) Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. Eur J Immunol 35: 2617-2626.
46. Maraskovsky E, Chen WF, Shortman K (1989) IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143: 1210-1214.
47. Giovarelli M, Santoni A, Jemma C, Musso T, Giuffrida AM, et al. (1988) Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol 141: 2831-2836.
48. Abel K, La Franco-Scheuch L, Rourke T, Ma ZM, DeSilva V, et al. (2004) Gamma Interferon-Mediated Inflammation Is Associated with Lack of Protection from Intravaginal Simian Immunodeficiency Virus SIVmac239 Challenge in Simian-Human Immunodeficiency Virus 89.6-Immunized Rhesus Macaques. J Virol 78: 841-854.
49. Reinhart TA, Fallert BA, Pfeifer ME, Sanghavi S, Capuano S 3rd, et al. (2002) Increased expression of the inflammatory chemokine CXC chemokine ligand 9/monokine induced by interferon-gamma in lymphoid tissues of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. Blood 99: 3119-3128.
50. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, et al. (2002) Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vectorinduced toxicity. J Virol 76: 5711-5719.
51. Sun Y, Bailer RT, Rao SS, Mascola JR, Nabel GJ, et al. (2009) Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 83: 10596-10604.
52. Perreau M, Pantaleo G, Kremer EJ (2008) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205: 2717-2725.
53. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
54. Fulton RB, Meyerholz DK, Varga SM (2010) Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 185: 2382-2392.
55. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, et al. (2007) Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 204: 2159-2169.
56. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB (2010) Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207: 1409-1420.
57. Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, et al. (2012) Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 119: 5155-5163.
58. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
59. Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, et al. (2011) Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study. AIDS 25: 153-158.
60. Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, et al. (2008) With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 82: 11181- 11196.
61. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, et al. (2005) The Tolllike receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 79: 14355-14370.
62. Abel K, Compton L, Rourke T, Montefiori D, Lu D, et al. (2003) Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 77: 3099-3118.
63. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.